PT - JOURNAL ARTICLE AU - ANDRI ANDREOU AU - SOFIA TRANTZA AU - DEMETRIOS FILIPPOU AU - NIKOLAOS SIPSAS AU - SOTIRIOS TSIODRAS TI - COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2 AID - 10.21873/invivo.11946 DP - 2020 Jun 01 TA - In Vivo PG - 1567--1588 VI - 34 IP - 3 suppl 4099 - http://iv.iiarjournals.org/content/34/3_suppl/1567.short 4100 - http://iv.iiarjournals.org/content/34/3_suppl/1567.full SO - In Vivo2020 Jun 01; 34 AB - Background: On March 11, 2020, the World Health Organization (WHO) declared the outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people have suffered and died, making the need for a treatment of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) more crucial than ever. Materials and Methods: The authors carried out a search in PubMed, ClinicalTrials.gov and New England Journal of Medicine (NEJM) for COVID-19 to provide information on the most promising treatments against SARS-CoV-2. Results: Possible COVID-19 agents with promising efficacy and favorable safety profile were identified. The results support the combination of copper, N-acetylcysteine (NAC), colchicine and nitric oxide (NO) with candidate antiviral agents, remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2. Conclusion: The authors propose to study the effects of the combination of copper, NAC, colchicine, NO and currently used experimental antiviral agents, remdesivir or EIDD-2801, as a potential treatment scheme for SARS-COV-2.